Checkpoint kinase 2 (CHEK2) is a DNA damage-activated protein kinase implicated in cell cycle checkpoint control. The significance of CHEK2 alterations for breast cancer incidence and clinical behavior is not clear. In this study we determined the mutational spectrum and the level of promoter hypermethylation of CHEK2 gene in a group of 145 Bulgarian patients with breast cancer. A special emphasis was put on the clinical impact of CHEK2 alterations for breast cancerogenesis.
differentiated cells [7] . In response to DNA damage induced by ionizing radiation, CHEK2 is activated through phosphorylation of Thr68 by ATM protein [5, [8] [9] [10] . When double strand breaks are caused by UV irradiation or hydroxyurea treatment, CHEK2 is likely to be activated by ATR kinase [10, 11] . After oligomerization and auto-phosphorylation [12] , CHEK2 kinase moves throughout the nucleoplasm to transmit the damage signal by phosphorylating several essential cell-cycle proteins including: p53 [11] , Cdc25A [12] and Cdc25C phosphatases [9] and BRCA1 [13] . This triggers cellular pathways are involved either in cell-cycle arrest at G1/S, S, and G2/M phases [14, 15] and DNA repair, or apoptosis [5, 16] .
The first evidence suggesting implication of CHEK2 in cancer development was the germline mutation 1100delC found in several Li-Fraumeni and Li-Fraumeni-like families [17] . Importantly, germ-line mutations within the CHEK2 gene have been reported in a subset of Li-Fraumeni families who have a wild-type p53, suggesting that CHEK2 may function as a tumor suppressor. The consideration of CHEK2 as a new tumor suppressor gene has been supported by the identification of germline and somatic mutations in a range of human tumors including breast, colon, ovarian, vulva, prostate and others [18] [19] [20] [21] [22] [23] [24] [25] [26] . On that basis CHEK2 is proposed as a multiorgan cancer susceptibility gene [27] . CHEK2 frequency and spectrum of mutations displayed considerable differences between populations and between familial and sporadic cases. Lately the 1100delC variant is evidently associated with a threefold increased risk of breast cancer in heterozygous women from the general population and may also increase the risk of other cancers [28] . In contrast to germ-line mutations in family cases, which are extensively studied, limited data on CHEK2 mutational frequency and spectrum in sporadic breast cancer is available. The CHEK2 somatic mutations in sporadic breast cancer are relatively rare [29] , and some studies assumed the possibility that, except genetic alterations, alternative mechanisms like epigenetic promoter hypermethylation could silence CHEK2 expression [20] . Promoter hypermethylation may serve as a basis for cancer development and has been described in several tumor suppressor genes like the RB gene in retinoblastoma [30] , the VHL gene in clear cell renal carcinoma [31] , the ATM gene in head and neck squamous cell carcinoma [32] , the BRCA1 gene in sporadic breast cancer [33] and others. Limited studies investigated the hypermethylation status of CHEK2 gene in breast [20, 29] , lung [34, 35] , lymphoid [36] , non Hodgkin lymphomas [37] , vulval [22] , ovarian [20] , colorectal tumors [38] , gliomas [39] .
So far, a general clinical impact of CHEK2 cannot be established due to the limited populations studied and the specificity in type and frequency of the found alterations. This study represents a combined genetic and epigenetic analysis of CHEK2 gene in sporadic breast cancer with a special emphasis on evaluation of CHEK2 clinical significance. The frequency and spectrum of genetic alterations and the level of epigenetic promoter hypermethylation in CHEK2 were determined in a group of 145 breast cancer patients. Specific mutational profile of CHEK2 gene for the Bulgarian population was found. Statistically significant clinical correlations were registered.
Patients and methods
Breast tumors were obtained from 145 Bulgarian female unrelated patients who were treated at the Thoracic Surgery Clinic of the National Oncological Centre (Sofia, Bulgaria) between 2000 and 2003. Cases were staged according to the TNM classification of Union International Contre le Cancer (UICC). The age of breast cancer women was in the range of 29-88 years, with a mean age of 54.4 years. Histologically, 130 invasive ductal carcinomas and 15 invasive lobular carcinomas were identified. Six patients had highly differentiated tumors (G1), 103 -moderately differentiated (G2) and 36 -poorly differentiated (G3). Ninety-two patients had negative nodal status and 53 -positive. Sixty-four patients were ER-negative, 81 -ER-positive. PR-negative were 64 patients, PR-positive -81. Tumor samples were previously characterized according to p53, BRCA1, ATM, PIK3CA mutational status and HER2 level of expression [40] . Patients underwent adjuvant therapy according to the accepted practice guidelines at that time. The women were followed for a median period of 69 months (range from 11 to 96 months). The follow-up time began at the time of surgery and ended in November 2008 or at the date of death. Blood samples of clinically healthy persons were used as negative controls. Written consent was taken from all participants in the study. Clinical information was obtained from the existing medical records and is presented in a way preventing patients' identification.
DNA isolation. Tumor DNA was isolated from fresh frozen breast tumors by a standard Proteinase K/Phenol procedure including tissue homogenization in lysis buffer (10mM Tris/ HCl pH 8.3, 400mM NaCl, 2mM EDTA-Na, 0.14mg/ml Proteinase K, 1% SDS) at 37 o C for 48 h, phenol/chloroform/isoamyl alcohol purification and ethanol precipitation. DNA was isolated from blood sample of healthy controls by a standard procedure. DNA concentration and purity was determined using BioSpec-nano Spectrophotometer (Shimadzu Biotech).
Single-strand conformational polymorphism analysis. The 14 coding exons of the CHEK2 were amplified using 15 primer sets according to Liu Wei-Dong et al [41] (Table 1) . PCR reactions were done in a total volume of 25 µl containing 50 ng of template DNA, 1x PCR buffer, 2.25 mM MgCl 2 , 0.2 mM of each dNTP, 100 nM of each primer and 0.5 units of Taq DNA polymerase (Netzyme). The cycling reactions included 35 cycles of denaturation at 94°C for 30 sec (first cycle -5 min), annealing at the appropriate temperature (see Table 1 ) for 30 sec and elongation at 72°C for 30 sec (last cycle -12 min.).
The amplified products were denatured in 95% formamide, 0.01 N NaOH (1:1.4) at 95°C for 10 min and separated on native polyacrylamide gels in 1xTBE buffer at 15 mA, 4°C. The polyacrylamide gel concentration varied between 6 to 14% depending on the exon. Modified silver staining method was applied for visualization. Briefly, the gels were soaked in 50% methanol for 1 h, then transferred to ammonium-silver solution, containing 0.02 N NaOH, 0.375% NH 4 OH, and 0.8% AgNO 3 for 15 min and washed with 500 ml dH 2 O for 10 min. The staining reaction was developed by the use of 0.01% citric acid, 0.035% formaldehyde, and the gels were fixed in 0.5% acetic acid.
Amplified products with altered electrophoretic mobility were purified (GFX PCR DNA and Gel Band Purification Kit, Amersham Biosciences) and sequenced on ABI PrismTM 310 fluorescent sequencing analyzer (DYEnamicTM ET Terminator Cycle Sequencing Kit, Amersham Biosciences) following the manufacturers' instructions. To confirm the mutation all mutant samples were subsequently sequenced in the reverse direction. The sequence data of CHEK2 gene was obtained from GenBank.
Methylation-sensitive SSCP. The methylation status of CHEK2 promoter was determined by Methylation-sensitive PCR-SSCP analysis of sodium bisulfite-converted DNA. To convert DNA, EZ DNA Methylation KitTM was used following the manufacturer's recommendations (Zymo Research Corporation). One μg of DNA of each sample was subjected to conversion. The obtained pure modified DNA was further PCR analyzed using four sets of primers (MIP2, MIP3, MIP4, and MIP5) covering a total of CpGs in the distal CpG island (located 6,000-8,000 bp upstream of the translation initiation site), and one set of primers (MIP1) targeting the proximal CpG region (300-600 bp upstream of the translation initiation site) ( Table 1) . Primer sequences and amplification conditions were according to Louise H. Williams [20] . The PCR products were SSCP analyzed as described above. We included in each assay a totally methylated in vitro DNA (Zymo Research) as a positive control, and a normal blood sample DNA as a negative control. The methylation status of representative methylation-sensitive SSCP products was confirmed by bisulfite sequencing (ABI PrismTM 310).
Statistical analysis. The relationship between СНЕК2 alterations and clinico-pathological characteristics of patients was evaluated by Fisher's exact test and the Chi-squared test. Overall survival (OS) was estimated by the Kaplan-Meier method, and differences between survival curves were assessed for statistical significance using the log-rank test. Cox proportional hazards regression model was used to calculate the hazard ratios (HR) and their 95% confidence intervals (95%CI) for each variable in the univariate and multivariate analyses. All p-values were two-sided, and results were considered statistically significant at p less than 0.05. Analyses were done with the SPSS software package (SPSS Inc., Chicago, IL, USA).
Results
Mutational analysis of CHEK2 gene. The group of 145 BC patients was assessed for CHEK2 mutations by PCR-SSCPSequencing analysis. Mutations in CHEK2 were found in 14 separate patients who had no family relationship (14/145 i.e. 9.65 %). None of the patients carried more than one CHEK2 mutation. All mutations were visualized as extra bands with altered electrophoretic mobility in the mutant samples 
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( Fig. 1, I A -lanes 1, 2, 3; II A -lane 1 and 2; III A -lane 3). Healthy persons were used as negative controls in the PCR-SSCP analysis (Fig. 1, I A -lane 4; II A -lane 3; III A -lanes 1 and 2). The PCR products with aberrant migration on the SSCP gel were purified and sequenced to determine the type of mutation (Table 2) . CHEK2 mutations were mapped to exons 1b, 12 and 13. All of the found alterations were novel and were either missense or silent. We found nine identical silent variants A to G at a position 237 bp (Glu79Glu) (Fig.  1, I B) , three C to T base substitutions at a position 1427 bp, leading to Thr476Met amino acid change (Fig. 1, II B) , and two C to G substitutions at a position 1520 bp altering the amino acid composition of the protein (Ala507Gly) (Fig.  1, III B) . Methylation analysis of the CHEK2 promoter. Methylation-sensitive SSCP was used to determine the methylation status of two distinct CpG clusters located upstream of the ATG. To assess the methylation status two controls -negative (blood DNA isolated from healthy persons) and positive (totally methylated in vitro DNA) were used in each electrophoresis. In all tumor samples the distal CpG cluster is not methylated and showed migration profile identical with the negative control. Reversely, the proximal CpG cluster is totally methylated and had migration profile identical with the positive control in all of the cases.
Mutational gene status in relation to clinico-pathological and molecular characteristics. To estimate the clinical impact of altered CHEK2 by itself, independent of the type of alteration, we compared the CHEK2 genetic status of the patients with standard prognostic factors including age of diagnosis, tumor size (T), nodal (N) status, grade of malignancy (G), histological type (HT), estrogen (ER) and progesterone receptor (PR) status (Table 3 ; Column "CHEK2 status"). In addition to the clinico-pathological characteristics of the patients, several tumor molecular characteristics previously found as p53, ATM, PIK3CA, HER2 status were included in the analysis [40] (Table 3) . We found that CHEK2 mutational status correlated significantly with lobular histological type (p=0.04). A tendency for higher frequency of the PR + status in CHEK2 + patients was found (p=0.092). To identify if the specific type of the found CHEK2 variants has a specific clinical impact we further divided the CHEK2 positive patients into two groups: one with missense variants and the other -with silent variants. Patients with the missense types Thr476Met (three patients) and Ala507Gly (two patients) were combined in a common group due to their limited number. The results showed that CHEK2 missense variants were significantly associated with ATM + status (p=0.046) (Table 3; Column "Missense variants"). All patients with CHEK2 missense mutations were ER positive (p=0.067). Statistically significant correlation (p=0.004) was found between the silent variants and PR status (Table 3 ; Column "Silent variants"). All patients with silent variants were progesterone receptor positive.
Mutational gene status and overall survival. Overall survival of the studied group was estimated to 75.86% (110/145). Kaplan-Meier analysis showed a decrease in OS of patients with CHEK2
+ status compared to CHEK2 -though not statistically significant (p = 0.6301).
To estimate the hazard ratio (HR) according to the CHEK2 status, univariate and multivariate Cox proportional-hazards regression model was used (Table 4 ). The multivariate model included the clinico-pathological and molecular characteristics of the patients discussed above. A threefold independent increase in the risk of death (HR = 3.295, 95%CI 0.850-12.778, p = 0.085) in CHEK2 + patients was found.
Another independent marker which strongly correlated with increased mortality rate was the tumor size (HR = 4.701, 95% CI 1.536-1.392, p = 0.007). Negative, though not independent effect on survival had p53 mutations (HR = 2.28, 95% CI 0.999-5.239, p = 0.05).
Discussion
Breast cancer is rather too heterogeneous and no general molecular phenotype related of the disease could be outlined. Breast carcinogenesis is a result of disruption of cellular pathways, in which key tumor suppressor genes and protooncogenes are involved: BRCA1and BRCA2 genes, p53, ATM, PIK3CA, HER2, CHEK2, PTEN and others. Of the BC related genes, CHEK2 is a key kinase implicated in the regulation of the cell cycle. Despite the intensive studies during the recent years, the complete mutational spectrum and the clinical significance of CHEK2 have not yet been fully elucidated. The established CHEK2 mutational profile shows considerable heterogeneity, both with respect to spectrum and frequency of mutations, and their presence (or absence) in the different populations [6, 42] . Several moderately penetrant CHEK2 [18, 28, [43] [44] [45] . These variants seem not to be present in all populations; their frequency varies in the general population, and is higher in breast cancer patients. In addition, some rare, missense mutations, small deletions and nonsense mutations have been identified [21, [46] [47] [48] . Some of these missense CHEK2 mutants have been shown to be unstable or to affect the activation of the encoded protein, indicating that they are likely to be pathogenic [49] [50] . No data on CHEK2 mutational spectrum in Bulgarian patients with breast cancer was so far available. Our results showed specificity in the spectrum of CHEK2 mutations. Interestingly, the CHEK2 variants discussed above are not present in the studied group of Bulgarian patients. However, novel alterations were found: Glu79Glu (A to G), Thr476Met (C to T), Ala507Gly (C to G). The mutation Thr476Met (C to T) maps to the kinase domain of CHEK2 and is likely to disrupt the main function of the protein. The Glu79Glu (A to G) variant is located between SCD and FNA domains, and the mutation Ala507Gly (C to G) is close to the C -terminal. Although these two variants do not affect the functional domains of the protein, they may alter the stability of mRNA and protein as well as its interactions with other proteins.
Our results showed that mutational CHEK2 status significantly correlated with several clinico-pathological parameters including lobular histological type and positive progesterone receptor status. Statistically significant correlation with the lobular histological type is visible when mutated CHEK2 is considered independent of the type of mutation. The observation was not registered when separate variants were taken into account, probably due to the smaller size of the excerpt. However, the tendency that patients with a CHEK2 alteration had lobular type of breast carcinoma remained. Invasive lobular carcinoma is the second most common type of breast cancer (10-20%) . It is considered to have a better prognosis than ductal carcinoma [51] with better survival rates of patients [52] . Similar to our findings Huzarski et al. [53] suggested a strong association of CHEK2 I157T allele with lobular breast carcinoma among BC patients in Poland. Progesterone and estrogen receptors are considered as breast cancer biomarkers with implications in prognosis and therapy. Over 70% of breast cancers are ER and PR positive [54] , and often respond to selective ER modulators such as Tamoxifen, which acts to inhibit estrogen by blocking the ER [55] . When hormone therapy is applied in ER positive patients, good therapeutic outcome is to be expected. Several studies found a correlation between 1100delC mutation and hormone receptor positive status [56, 57] .
In addition to clinico-pathological parameters, the genetic status of several BC related genes was investigated in relation to CHEK2 status. Most of these genes are involved in pathways which regulate the cellular response to genotoxic stress [58] . CHEK2 kinase directly interacts with some of these proteins, including ATM kinase and p53 transcription factor. In this study we found an interesting association between CHEK2 missense mutation and ATM positive status. АТМ gene is a sensor of DNA damage and upon ATM inactivation the signal transduction to the target genes is disrupted. The impossibility of effective DNA repair leads to accumulation of mutations, thus the dysfunction of ATM and CHEK2 can further facilitate tumorigenesis [59, 60] . We also found a relationship between CHEK2 and p53 mutational gene status. Of a total of sixteen p53 positive tumors [40] only one had in addition a mutation in CHEK2. It seems like p53 and CHEK2 mutations somehow are mutually incompatible. In support to this is the observation that germ-line CHEK2 mutations are present in Li-Fraumeni families with a wild-type p53.
Although mutated CHEK2 correlated with more favorable clinical characteristics (lobular histological type and PR+ status), it increased the risk of death in positive patients. A possible explanation of this observation is that CHEK2 mutational status has by itself a negative prognostic charge, which is reduced under the influence of the positive prognostic indica- tors. The positive PR status by itself, as well as the lobular type of tumors, presumes a good therapeutic response and better outcome of patients. In combination with CHEK2 mutations, however, a slight increase in the risk of death (Univariate Cox proportional hazard regression model) and decrease in overall survival (Kaplan-Meier analysis) were registered. When the influence of all studied tumors and molecular characteristics are taken into account and their effect is neglected (in the Multivariate Cox proportional hazard regression model), the independent impact of mutated CHEK2 can be observed. Thus, the independent CHEK2 + considerably increased the risk of death in mutation carriers.
Several studies presume the implication of epigenetic (in addition to genetic) mechanisms in loss of CHEK2 function [20] . A possible epigenetic cancer related event is the promoter hypermethylation. Hypermethylation in CHEK2 promoter was found in lung [34] , colorectal cancer [38] and Hodgkin's lymphoma cell lines [36] . Higher CHEK2 hypermethylation frequency was detected in non-small-cell lung carcinoma -28.1%, and in colorectal cancer -10% [34, 38] . In gliomas СНЕК2 promoter was hypermethylated only in its proximal high CpG dinucleotides region [39] . With respect to BC, limited data available showed lack of abnormal CHEK2 hypermethylation [20, 29, 61] . This was also supported by our results, which are similar to the results of Williams LH et al. [20] . The data indicated that the proximal CpG cluster is totally methylated in all tumor samples. Such methylation profile is also present in the studied normal tissue samples, which indicates that it is probably not related to breast tumorigenesis. Reversely, the distal CpG cluster is not methylated either in tumor samples, or in the controls. This data suggest that the distal CpG region may not be significant in regulation of gene transcription and therefore in tumorigenesis.
Conclusion
This study provided the first data on the genetic profile and promoter methylation status of CHEK2 gene in Bulgarian breast cancer patients. Our data indicate the significance of genetic inactivation of CHEK2 in sporadic breast carcinogenesis. However, CHEK2 hypermethylation is probably less essential in this cancer type. Several novel CHEK2 variants were registered presuming specificity of CHEK2 mutational profile for the Bulgarian population. Though CHEK2 mutational status correlated with more favorable clinical characteristics, including positive progesterone receptor and lobular histological type, it independently increased the risk of death in these patients.
